SCHEMBL6041147

SCHEMBL6041147

N#Cc1ccc(C(=O)Nc2cccc(Nc3nccc(-c4ccncn4)n3)c2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 13/20 0.76
BCR P11274 11/20 0.76
PDGFRB P09619 7/20 0.76
PDGFRA P16234 7/20 0.76
PRKCA P17252 4/20 0.76
SRC P12931 7/20 0.60
PRKCD Q05655 3/20 0.60
PRKD3 O94806 1/20 0.57
PRKCG P05129 1/20 0.57
PRKCB P05771 1/20 0.57
PRKCH P24723 1/20 0.57
PRKCI P41743 1/20 0.57
PRKCE Q02156 1/20 0.57
PRKCQ Q04759 1/20 0.57
PRKCZ Q05513 1/20 0.57
PRKD1 Q15139 1/20 0.57
ABL2 P42684 2/20 0.57
JAK2 O60674 1/20 0.52
CYP11B1 P15538 1/20 0.52
CYP11B2 P19099 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4896152 0.89 ABL1 (0.84) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL4905407 0.89 ABL1 (0.74) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL9642 0.86 ABL1 (1.00) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL6041113 0.82 ABL1 (0.57) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL6041110 0.82 ABL1 (0.57) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL4896241 0.80 ABL1 (0.71) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL4903369 0.80 ABL1 (0.71) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL4892512 0.79 ABL1 (0.67) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL3123402 0.78 ABL1 (0.74) ABL1BCRPDGFRBPDGFRAPRKCA
SCHEMBL4901694 0.77 ABL1 (0.83) ABL1BCRPDGFRBPDGFRAPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060217404-A1 Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) 2006-09-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217404-A1 Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases PRNP, PPM1D, PPM1F ABL1 904/4885BCR 1230/4885PDGFRB 2329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.